<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-98165</identifier>
<setSpec>1576-9895</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Pneumonia with fatal outcome in a patient with rheumatoid arthritis treated with adalimumab</dc:title>
<dc:description xml:lang="en">Summary. Drugs with anti-TNF-alpha activity represent an important therapeutic advance for a large number of inflammatory conditions such as methotrexate resistant rheumatoid arthritis, psoriatic arthritis, seronegative ankylosing spondylitis or inflammatory bowel disease. Unfortunately, the use of this type of immunomodulators is not exempt of  adverse effects and pulmonary complications such as interstitial pneumopathies or opportunistic infections. We present the case of a female patient diagnosed of rheumatoid arthritis treated with adalimumab who developed an acute distress picture whose clinical course was very bad in spite of the antibiotic and high dose steroid treatment (AU)</dc:description>
<dc:creator>Martín, A</dc:creator>
<dc:creator>Cantabrana, A</dc:creator>
<dc:creator>Figueira, M</dc:creator>
<dc:creator>Taoroni, A</dc:creator>
<dc:creator>Acosta, O</dc:creator>
<dc:creator>Ramírez, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Resumen. Los fármacos con actividad anti-TNFalfa representan un importante avance terapéutico para un gran número de patologías inflamatorias tales como la artritis reumatoide resistente a metotrexato, artritis psoriásica, espondilitis anquilosante  seronegativa o la enfermedad inflamatoria intestinal. Desafortunadamente, el uso de este tipo de inmunomoduladores no está exento de efectos adversos y de complicaciones pulmonares tales como neumopatías intersticiales o infecciones  oportunistas. Presentamos el caso de una paciente diagnosticada de artritis reumatoide en tratamiento con adalimumab que desarrolló un cuadro agudo de distrés cuyo curso clínico fue nefasto a pesar de tratamiento antibiótico y esteroideo a dosis altas (AU)</dc:description>
<dc:source>Rev. patol. respir;13(1): 40-43, ene.-mar. 2010. ilus</dc:source>
<dc:identifier>ibc-98165</dc:identifier>
<dc:title xml:lang="es">Neumonía de evolución fatal en paciente con artritis reumatoide tratada con adalimumab</dc:title>
<dc:subject>^d7336^s22020</dc:subject>
<dc:subject>^d11443^s22036</dc:subject>
<dc:subject>^d31333^s22036</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d1178^s22057</dc:subject>
<dc:subject>^d1178^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201003</dc:date>
</metadata>
</record>
</ibecs-document>
